拜瑪林製藥 BMRN 深 滬
等待開盤 03-26 09:30:00 美东时间
55.59
+1.500
+2.77%
華盛通- 最 高55.73
- 今 開54.61
- 成交量 194.74万股
- 最 低 54.61
- 昨 收 54.09
- 總市值 106.91亿
- 52周最高 66.275
- 市盈率 靜 30.80
- 換手率 1.01%
- 52周最低 50.76
- 委 比 58.81%
- 總股本 1.92亿
- 歷史最高 151.75
- 量 比 0.80
- 振 幅 2.07%
- 歷史最低 23.735
- 每 手 1
- 風險率 3.79%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Top 3 Health Care Stocks That Are Set To Fly In March
Opportunity to buy undervalued health care stocks. RSI is a momentum indicator that compares strength on up and down days. Here's a list of oversold stocks with RSI near or below 30.
03-20 18:23
BioMarin shares drop 4% as Voxzogo trials are discontinued
BioMarin Pharmaceutical's (BMRN) shares fell on Monday after the company said it would discontinue dosing and enrollment in its phase 2 trials for Voxzogo in Turner syndrome, SHOX-deficiency, and Aggr...
03-16 20:48
BioMarin halts Phase 2 VOXZOGO dosing and enrollment in Turner syndrome, SHOX-deficiency and ACAN-deficiency trials
BioMarin halts Phase 2 VOXZOGO dosing and enrollment in Turner syndrome, SHOX-deficiency and ACAN-deficiency trials BioMarin discontinued dosing and enrollment in its Phase 2 VOXZOGO trials for Turner syndrome, SHOX-deficiency and ACAN-deficiency after several slipped capital femoral epiphysis event
03-16 20:32
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on top names. See all changes on analyst ratings page.
03-11 20:19
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz
BridgeBio's rare-disease pipeline draws investor attention as new therapies near regulatory filings and potential commercial launches.
03-11 02:49
美股大行评级 | 7家上调，3家下调！CrowdStrike绩后大行评级现分歧；罗斯百货、塔吉特、Viking获多家大行上调目标价
今日重点评级关注：古根海姆：维持Dianthus Therapeutics"买入"评级，目标价从100美元升至200美元；HC Wainwright & Co.：维持Amylyx Pharmaceuticals"买入"评级，目标价从28美元升至34美元
03-05 13:56
Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $105
Barclays analyst Eliana Merle maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $80 to $105.
03-04 22:38
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients
The FDA approved BioMarin's supplemental BLA for Palynziq, a treatment for PKU in adolescents 12 and older.
03-02 19:10
